Research suggests that targeting certain molecular interactions may be a therapeutic strategy in childhood leukemia. The overexpression of MDM2, potentially induced by ETV6/RUNX1, may be blocked by Nutlin-3, which could reactivate p53 signaling. Other potential therapeutic vulnerabilities in acute lymphoblastic leukemia may involve FLT4 activation, BCL-2 inhibition, and Core Binding Factor addiction.